AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Proxy Contest (September 2011)

9 slides from AMAG Pharmaceuticals's proxy contest presentation, Sep 30, 2011

  1. Slide 1: AMAG Shareholders Vote Against The Allos Merger

    AMAG Shareholders Vote Against The Allos Merger Institutional Shareholder Services, Inc. September 30, 2011 MSMB Capital Management LLC

  2. Slide 2: Disclaimer

    Disclaimer THIS PRESENTATION IS NOT A CONSENT STATEMENT OR A PROXY STATEMENT, AND IT DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITIES OR A SOLICITATION OF ANY CONSENT OR PROXY. ANY SUCH SOLICITATION WILL BE MADE ONLY BY A WRITTEN DEFINITIVE CONSENT STATEMENT

  3. Slide 3: AMAG's Severe Underperformance

    AMAG's Severe Underperformance • Under any relevant timeframe, AMAG's stock price has severely underperformed its peers * 1-, 3- and 5-year stock price performance through August 1, 2011 (the day prior to the public announcement of MSMB's proposal).

  4. Slide 4: The Allos Transaction Is Not In The Best Interests of AMAG Shareholders

    The Allos Transaction Is Not In The Best Interests of AMAG Shareholders • A vote "AGAINST" the Proposed Allos Merger helps to preserve shareholders' opportunity to receive the all-cash premium provided by MSMB's Proposed Offer which, if consummated, provides significantly greater value to the AMAG s

  5. Slide 5: Folotyn Analysis

    Folotyn Analysis The FDA Orange Book confirms the 9/24/2016 expiry of Orphan Status for Folotyn Amag/Allos have less than 5 years to generate cash flow from this "disappearing" asset Because Amag and Allos have indicated the merged company will only break-even in 2013, the cash flows from Folotyn wi

  6. Slide 6: The Allos Transaction Is Not In The Best Interests of AMAG Shareholders, cont.

    The Allos Transaction Is Not In The Best Interests of AMAG Shareholders, cont. AMAG's stated strategic rationale for the Proposed Merger is unfounded. There are not obvious synergies between AMAG and Allos. While there are a variety of applications of Feraheme, it is not primarily prescribed by onco

  7. Slide 7: The Allos Transaction Is Not In The Best Interests of AMAG Shareholders, cont.

    The Allos Transaction Is Not In The Best Interests of AMAG Shareholders, cont. • AMAG's management is unprepared to handle the integration of Allos. The Proposed Merger contemplates a complex integration of Allos and AMAG which we believe AMAG's management is ill-equipped to handle. AMAG's managemen

  8. Slide 8: AMAG's Bloated Infrastructure

    AMAG's Bloated Infrastructure With SG&A running at a staggering 128% of sales, AMAG's infrastructure appears bloated compared to other pharmaceuticals. Professional services, HR, legal, BD, communications and finance all appear to be unreasonably high for a company the size of AMAG. Revenue SG&A % o

  9. Slide 9: Vote Against The Proposed Merger on the Blue Proxy Card

    Vote Against The Proposed Merger on the Blue Proxy Card If you have questions or need assistance in voting your shares, please call our proxy solicitor, Innisfree M&A Incorporated, at 212-750-5833.

AMAG Pharmaceuticals — Proxy Contest (September 2011) on 6ix